The Dutch business of Rhythm Pharmaceuticals (Nasdaq: RYTM) has acquired Xinvento, a Netherlands-based biotech focused on therapies for congenital hyperinsulinism (CHI).
Rhythm is working on treatments for hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, making the expansion into CHI a natural fit for its scientific expertise.
CHI is a rare and life-threatening genetic condition which leads to excess insulin being secreted, resulting in hypoglycemia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze